Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

M.D. Anderson Cancer Center23 enrolled

Overview

The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.

Before treatment starts, patients will have a complete check-up, blood tests, a chest x-ray, and a CT scan. Other scans or tests will be done as needed. Women able to have children must have a negative urine pregnancy test. A blood sample will be taken for routine testing once a week during treatment and a month after treatment ends. Patients will also be asked to complete two questionnaires before they start treatment, before Courses 3 and 5, and at the end of treatment. These questionnaires will help researchers understand how this drug affects patients' daily lives and also identify the side effects caused by this treatment. Each questionnaire will take about 10 minutes to complete. Patients in this study will be given paclitaxel and carboplatin through a catheter (tube) placed in a vein. Paclitaxel is given first (over 3 hours) followed by carboplatin (over 1 hour). All treatment is given in the outpatient department at M.D. Anderson Cancer Center. Patients may receive up to 6 courses of treatment. If the disease gets worse or intolerable side effects occur, patients will be taken off study. -Before each course of treatment, patients will have a checkup. At each checkup, patients will have a physical exam and blood tests. Another CT scan will be done after the third course of treatment. A complete physical exam and a CT scan will also be done at the end of treatment. This is an investigational study. Both of the study drugs are FDA approved. Their use together in this study is experimental. A total of 50 patients will take part in this multicenter study. About 35 will be enrolled at M. D. Anderson.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Mixed Tumor, Mullerian

Interventions

CarboplatinDRUG

AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses

PaclitaxelDRUG

175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with histologically confirmed advanced (IIIb, IIIc, IVa and IVb) or recurrent (all stages) MMMT. 2. Prior chemotherapy is permitted with the exception of patients previously treated with platinum and/or taxol chemotherapy for this disease. 3. Women of any racial and ethnic group. 4. Eastern Cooperative Oncology Group (ECOG) performance status \</= 2. 5. Expected survival of \>/= 12 weeks. 6. Patients must have recovered from the side effects of prior therapy (chemotherapy, surgery, or radiation) before entering the study. 7. Adequate liver, renal, and bone marrow function, defined as: a total bilirubin value \</= 1.5 mg/dL; serum glutamic pyruvic transaminase (SGPT) \</= 2 times upper limit of normal or \</= 5 times upper limit of normal when liver metastases are present; serum creatinine \</= 1.5 mg/dL; Absolute neutrophil count (ANC) \>/= 1,500/ul; platelet count \>/= 100,000/ul. All qualifying laboratory parameters must be determined within 1 week prior to first treatment. 8. Participants must agree to practice approved methods of birth control (if applicable). 9. Patients must sign an institutionally approved informed consent. Exclusion Criteria: 1. Patients with a Zubrod performance status of 3 or greater. 2. Concurrent cancer chemotherapy, radiotherapy or surgery. 3. History of other malignancy (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 5 years. 4. Presence of known untreated brain metastases. 5. Overt psychosis or mental disability or otherwise incompetent to give informed consent. 6. Patients with an active systemic infection. 7. Patients with a serious intercurrent medical illness. 8. Patients with a history of neuropsychiatric or seizure disorders.

Locations (4)

Loma Linda Cancer Institute

Loma Linda, California, United States

MD Anderson Cancer Center

Orlando, Florida, United States

Lyndon Baines Johnson Hospital

Houston, Texas, United States

UT MD Anderson Cancer Center

Houston, Texas, United States

Outcomes

Primary Outcomes

Number of Participants With Overall Response

Overall response rate including complete (CR) and partial responses (PR) with measurable disease using Response Evaluation Criteria In Solid Tumors (RECIST) assessment. CR: Disappearance of all target and non-target lesions; no evidence of new lesions documented by 2 disease assessments at least 4 weeks apart. PR: At least 30% decrease in sum of longest dimensions (LD) of all target measurable lesions reference baseline sum of LD; no unequivocal progression of non-target lesions and no new lesions. Documentation by 2 disease assessments at least 4 weeks apart is required.

Time frame: 24 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.